Financing channel feed – Endpoints News

Financing channel feed

TYK Medicines seeks to launch new EGFR drug in China with $74M Hong Kong IPO

10 months ago

Investment in early-stage health tech startups climbed in the first half of 2024, report shows

11 months ago

Sanofi backs AnaptysBio’s $100M offering, helping catapult the biotech’s stock

11 months ago

Exclusive: Gates Foundation backs startup using optogenetics to manufacture biologics

11 months ago

Why a new health tech venture firm is investing only in founders with a healthcare background

11 months ago

Halda adds $126M to test oral drugs for prostate, breast cancer

11 months ago

Exclusive: MIT spinout launches with focus on improving DNA payloads for gene insertion

11 months ago

IDRx raises $120M for targeted GIST drug following leadership change

11 months ago

TPG reveals $580M life sciences fund, which has already backed multiple biotechs

11 months ago

Eisai picks SEED Therapeutics for molecular glue deal worth as much as $1.5B

11 months ago

Arie Belldegrun and team unveil $600M life sciences credit firm amid struggling biotech market

11 months ago

Exclusive: TCG, DCVC and Lux back new autoimmune biotech from Kallyope co-founder

11 months ago

Japanese government grants Shinobi $59M for cell therapy development

11 months ago

A new Apple Tree Partners biotech launches with $55M to make ‘pan-variant’ antivirals

11 months ago

MBX Biosciences rakes in $63.5M for peptide therapies

11 months ago

Exclusive: Devoted Health raises $112M, plots insurance markets expansion

11 months ago

Apogee and Spyre founder launches another autoimmune biotech, and it's got $80M to start

11 months ago

Exclusive: Ultragenyx secures first funds for Alzheimer's gene therapy spinout

11 months ago

With $144M Series B, Outpace Bio beats funding goal for solid tumor cell therapies

11 months ago

VC firm venBio secures $528M for ‘extremely selective’ fifth fund after recent IPOs, M&A exits

11 months ago

Rare disease biotech raises $47M Series C, plans for Phase 2 trial

11 months ago

As Amgen pursues GIP antagonism, a Novo Holdings-backed biotech does the same, boosting its Series A

11 months ago

RNA editing startup AIRNA raises $60M for clinical trial in rare liver disease

11 months ago

Exclusive: Startup aims to tackle ‘undruggable’ neuro targets with tech from Kevan Shokat's UCSF lab

11 months ago

First page Previous page 11 12 131415 16 17 Next page Last page